Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

ClinicalTrials.gov ID: NCT04906694

Public ClinicalTrials.gov record NCT04906694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intranasal STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.

Study identification

NCT ID
NCT04906694
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Enrollment
97 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 15, 2021
Primary completion
Jan 12, 2022
Completion
Jan 12, 2022
Last update posted
Feb 2, 2022

2021 – 2022

United States locations

U.S. sites
18
U.S. states
10
U.S. cities
18
Facility City State ZIP Site status
Future Innovative Treatments, LLC Colorado Springs Colorado 80907
Clinical Neuroscience dba CNS Healthcare Jacksonville Florida 32256
Med-Care Research Miami Florida 33165
Clinical Neuroscience Solutions Healthcare Orlando Florida 32801
Precision Research Center Tampa Florida 33614
Clinical Site Partners, Inc Winter Park Florida 32789
Randomize Now Peachtree City Georgia 30269
Revival Research Institute Dearborn Michigan 48126
Quality Clinical Research Omaha Nebraska 68114
Remington Davis Columbus Ohio 43215
Cyn3rgy Research Gresham Oregon 97030
WR-ClinSearch Chattanooga Tennessee 37421
Advanced Medical Trials Georgetown Texas 78628
Precision Comprehensive Clinical Research Solutions Grapevine Texas 76051
Centex Studies Inc. Houston Houston Texas 77062
LinQ Pearland Texas 77584
Epic Research Red Oak Texas 75154
Infectious Diseases Associates of Central Virginia Lynchburg Virginia 24501

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04906694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2022 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04906694 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →